

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060099 A2

(51) International Patent Classification⁷: A45C 11/00, 11/04, B65B 25/00

(74) Agents: JOHNSON, Philip S, et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(21) International Application Number:
PCT/US2003/039017

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 December 2003 (09.12.2003)

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/436,109 23 December 2002 (23.12.2002) US

(71) Applicant: JOHNSON & JOHNSON VISION CARE INC. [US/US]; 7500 Centurion Parkway, Jacksonville, FL 32256 (US).

(72) Inventors: PECK, James; 13587 Osprey Point Drive, Jacksonville, FL 32224 (US). DUBEY, Dharmesh; 9087 Starpass Drive, Jacksonville, FL 32256 (US). TOKARSKI, Michael; 500 N. Lakewood Run, Ponte Vedra Beach, FL 32082 (US). ZHANG, Qiang; 27 LaCosta Drive, Annandale, NJ 08801 (US). LI, Yufu; 11 Hughes Road, Bridgewater, NJ 08807 (US). ARNOLD, Steven; 26 Hideaway Lane, Sparta, NJ 07871 (US).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CONTACT LENS PACKAGES CONTAINING ADDITIVES

Lens A
Average Rating by Package Type



WO 2004/060099 A2

(57) Abstract: A package having an additive that does not adhere to a medical device enclosed therein.

**CONTACT LENS PACKAGES CONTAINING ADDITIVES
RELATED APPLICATIONS**

This application is a non-provisional filing of a provisional application,
U.S. Pat. App. No.60/436,109, filed on December 23, 2002.

5 **FIELD OF THE INVENTION**

This invention related to packages for storing contact lenses as well as methods of using and preparing these packages.

BACKGROUND

Contact lenses have been used commercially to improve vision since the 10 1950s. At first contact lenses were made of hard materials, which were relatively easy to handle and package for use, but were uncomfortable for many patients. Later developments, gave rise to softer more comfortable lenses made of hydrophobic hydrogels, particularly silicone hydrogels. These lenses are very pliable, but due to this texture and their chemical composition, 15 they present a number of problems with packaging.

Most contact lenses are packaged in individual blister packages having a bowl portion and a foil top, where the bowl portion is made from a hydrophobic material such as polypropylene. See U.S. Patent Nos. 4,691,820; 5,054,610; 5,337,888; 5,375,698; 5,409,104; 5,467,868; 5,515,964; 5,609,246; 20 5,695,049; 5,697,495; 5,704,468; 5,711,416; 5,722,536; 5,573,108; 5,823,327; 5,704,468; 5,983,608; 6,029,808; 6,044,966; and 6,401,915 for examples of such packaging, all of which are hereby incorporated by reference in their entirety. While polypropylene is resilient enough to withstand the sterilization steps of contact lens manufacture, this material has an affinity for contact 25 lenses made of silicone hydrogels. When silicone hydrogels are packaged in polypropylene bowls, the lenses stick to the bowl and cannot be removed from the package without damaging the pliable lenses. Therefore is a need to prepare a contact lens package that has resilient properties, but does not stick to the final product. It is this need that is met by the following invention.

30 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 illustrates the data for Lens A in different packages

Figure 2 illustrates the data for Lens B in different packages

Figure 3 illustrates the data for Lens C in different packages

DETAILED DESCRIPTION OF THE INVENTION

This invention includes a package for storing medical devices in a solution comprising, consisting essentially of, or consisting of, a molded base wherein the molded base comprises an additive, provided that

5 the medical device is not a contact lens consisting of acqualfilcon A coated with polyHema.

As used herein a "medical device" is any device that is stored or packaged in a solution and is used to treat a human disease. Examples of medical devices include but are not limited to ophthalmic devices that reside in

10 or on the eye. Ophthalmic devices includes but are not limited to soft contact lenses, intraocular lenses, overlay lenses, ocular inserts, and optical inserts. These devices can provide optical correction or may be cosmetic. The preferred medical devices of the invention are soft contact lenses made from silicone elastomers or hydrogels, which include but are not limited to silicone

15 hydrogels, and fluorohydrogels. Soft contact lens formulations are disclosed in U.S. Pat. App. No. 60/318,536, entitled Biomedical Devices Containing Internal wetting Agents," filed on September 10, 2001 and its non-provisional counterpart of the same title, filed on September 6, 2002, US Patent No. 5,710,302, WO 9421698, EP 406161, JP 2000016905, U.S. Pat. No.

20 5,998,498, US Pat. App. No. 09/532,943, U.S. Patent No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776, 999, U.S. Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat. No. 5,965,631. The foregoing references are hereby incorporated by reference in their entirety. The particularly preferred medical devices of the invention are soft contact lenses made from etafilcon A,

25 genfilcon A, lenefilcon A, polymacon, balafilcon A, lotrafilcon A. and silicone hydrogels as prepared in U.S. Pat. No. 5,998,498, U.S. Pat. App. No. 09/532,943, a continuation-in-part of US Pat App. No. 09/532,943, filed on August 30, 2000, U.S. Patent No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776, 999, U.S. Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat.

30 No. 5,965,631. These patents as well as all other patent disclosed in this application are hereby incorporated by reference in their entirety. The more particularly preferred medical devices of the invention are soft contact lenses, balafilcon A, lotrafilcon A, galyfilcon A, senofilcon A, or those made as

described in U.S. Pat. App. No. 60/318,536, entitled Biomedical Devices Containing Internal wetting Agents," filed on September 10, 2001 and its non-provisional counterpart of the same title, filed on September 6, 2002. The most particularly preferred medical devices are soft contact lenses made from either
5 galyfilcon A or senofilcon A.

The term "molded base" refers to any polymer, rubber, or plastic that can be formed into a receptacle for medical devices, where the size and shape of the base are determined by the device and other considerations known those who are skilled in the art of making or designing molded bases. For example
10 molded bases may be individual blister packages, secondary packages, or hydrating trays. The molded base may be prepared from any number of materials provided that those materials are compatible with the chemical and physical properties of the device. Examples of suitable materials include but are not limited to polypropylene, polyethylene, nylons, olefin co-polymers,
15 acrylics, rubbers, urethanes, polycarbonates, or fluorocarbons. The preferred materials are metallocenes polymers and co-polymers made of polypropylene, polyethylene, having a melt flow range of about 15 g/10 minutes to about 44 g/10 minutes as determined by ASTM D-1238. With respect to the shape of the molded base, examples of suitably shaped bases are disclosed in the
20 following patents which are hereby incorporated by reference in their entirety, U.S. Patent Nos. D 458,023; 4,691,820; 5,054,610; 5,337,888; 5,375,698; 5,409,104; 5,467,868; 5,515,964; 5,609,246; 5,695,049; 5,697,495; 5,704,468; 5,711,416; 5,722,536; 5,573,108; 5,823,327; 5,704,468; 5,983,608; 6,029,808; 6,044,966; and 6,401,915. As in the cited references, the molded based is
25 sealed about the cavity that encloses the contact lens. Flexible cover sheets can be made from can be an adhesive laminate of an aluminum foil and a polypropylene film or any other extruded or co-extruded film that can be sealed to the top surface of the flange in order to form a hermetic seal for the medical device and the solution. Further, the base can be formed by any of a number
30 of known methods which include but are not limited to injection molding, transfer molding, skin packaging, blow molding, coinjection molding, film extrusion, or film coextrusion.

As used herein the term "additive" refers to a substance that is added to the polymer, rubber, or plastic prior to forming the molded base, where the material inhibits sticking, adherence, or adhesion of the medical device to the molded base. The additive is mixed with the remainder of the molded base

5 material and amount of additive present by weight percentage based on the total weight of the molded base material is greater than about 0.25 to about 10 weight percent, preferably greater than about 0.25 to about 5 weight percent, most preferably about 0.25 to about 3 weight percent. The preferred additives are glycerol monostearate (2%), polyvinylpyrrolidone (1% to 5%),

10 polyvinylpyrrolidone/maleic anhydride (1/1% to 5/5%), and succinic acid (5%). Polyvinylpyrrolidinone has a variety of molecular weight ranges (as indicated by the KD#) and consistencies (flake, powdered/micronized). When PVP KD90 is used as an additive, it is preferred that it is powdered/micronized.

The term "solution" refers to any liquid medium in which a medical device is stored. The preferred solutions are aqueous solutions contain physiological buffers. The particularly preferred solution is saline solution.

For example, if the medical device is a contact lens, it is preferred that the molded base is transparent to the degree necessary to permit visual inspection, UV sterilization or both. The preferred additives are glycerol monostearate present at about 2 weight percent, succinic acid present at about 5 weight percent, PVP KD90 present at about 1-5 weight percent, PVP/maleic anhydride present at about 1/1 to about 5/5 weight percent. If the inner surface of the medical device has a roughness of about 0.2 μm to about 4.5 μm , the preferred additives are maleic anhydride or PVP/maleic anhydride, 25 most preferably maleic anhydride.

Further, the invention includes a method of reducing the adherence of a medical device to its packaging, comprising, consisting essentially of, or consisting of, storing said medical device in a solution in a package comprising, consisting essentially of, or consisting of, a molded base wherein said molded base comprises an additive, provided that the medical device is not a contact lens consisting of acqualilcon A coated with polyHema. The terms molded base, medical device, solution and additive all have their aforementioned meanings and preferred ranges.

When soft contact lenses are prepared, the lenses cured to a hard disc and subsequently hydrated with water to give the non-sterilized final product. During this hydration step, soft contact lenses often stick to the surface of the hydration chamber and it would be useful to find a method of hydrating soft contact lenses which alleviates this problem.

To solve this problem, the invention includes a method of hydrating a contact lens comprising, consisting essentially of, or consisting of hydrating said lens in a molded base wherein said molded base comprises an additive. The terms molded base, medical device, solution and additive all have their aforementioned meanings. The preferred values for the medical device, the solution and the additive are as listed above. The preferred molded base is a square or a rectangle.

Others have tried to address the problem of a medical device adhering to its packaging. For example U.S. Pat App. No. 09/942,347, entitled "Textured Contact Lens Package," filed on August 29, 2001 and U.S. Pat. App. No. 10/183,133, entitled "Contact Lens Packages," filed on June 26, 2002 disclose solutions to this problem. The disclosure of these applications are hereby incorporated by reference in their entirety. Even though those methods address this problem, it is contemplated by the inventors of this patent application that the additives of this invention may be incorporated into the packaging of each of the cited references.

In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are meant only to suggest a method of practicing the invention. Those knowledgeable in contact lenses as well as other specialties may find other methods of practicing the invention. However, those methods are deemed to be within the scope of this invention.

EXAMPLES

The following abbreviations are used below

Ampacet 40604	fatty acid amide
30 ATOFINA 3924CWZ	Finacene Nucleated polypropylene having a melt flow of 55g/10 minutes, ASTM D1238. This material contains an antistat and a lubricant
Atmer 163	fatty alkyl diethanolamine Reg. No.107043-84-5

	Dow Siloxane MB50-321	a silicone dispersion
	Epolene E43-Wax,	maleic anhydride produced by Eastman Chemical
	Erucamide	fatty acid amide Registry No. 112-84-5
	Exxon 1605	Exxon Achieve, PP1605, a metallocene
5		polypropylene having a melt flow of 32 g/10 minutes, ASTM D-1238 (L)
	Exxon 1654	Exxon Achieve, PP1654, a metallocene isotactic polypropylene having a melt flow of 16 g/10 minutes, ASTM D-1238 (L)
10	Fina EOD-001	Finacene, a metallocene and isotactic polypropylene having a melt flow of 16g/10 minutes, ASTM D1238
	Flura	Registry No.7681-49-4
	Kemamide	fatty acid amide
15	Licowax	fatty acid amide
	Mica	Registry No. 12001-26-2
	Nurcrel 535 & 932	ethylene-methacrylic acid co-polymer resin Registry No. 25053-53-6
	Oleamide	fatty acid amide Registry No. 301-02-0
20	polyHema	poly hydroxy ethylmethacrylate having a molecular weight of greater than 1MM Dalton
	mPDMS	800-1000 MW monomethacryloxypropyl terminated polydimethylsiloxane
	Pluronic	polyoxypropylene-polyoxyethylene block co-polymer Registry No.106392-12-5
25	PVP	poly vinyl pyrrolidinone, wherein KD# refers to different known molecular weight distributions of poly vinyl pyrrolidinone
	Simma 2	3-methacryloxy-2-hydroxypropyloxy)propylbis(trimethylsiloxy)methylsilane
30	Super-Floss anti block	slip/anti blocking agent, Registry No. 61790-53-2
	Tetronic	alkyoxylated amine 110617-70-4
	Zeospheres anti-block	slip/anti blocking agent

Lens Preparations

5 Lens A Acquafilcon A lenses coated with polyhema having a molecular weight of about 1,000,000. See U.S. Pat App. No. 09/957,299, entitled "Soft Contact Lenses," filed on September 20, 2001, Example 27. The coating method is disclosed in U.S. Pat. App. No. 09/921,192, entitled "Method for Correcting Articles by Mold Transfer," filed on August 2, 2001.

10 Lens B Contact lenses prepared as described in U.S. Pat. App. No. 60/318,536, entitled Biomedical Devices Containing Internal wetting Agents," filed on September 10, 2001 and its non-provisional counterpart of the same title, filed on September 6, 2002, containing by weight percent 30% Simma 2, 19% mPDMS, 31% DMA, 6% PVP (MW 360,000), 0.8%EDGMA, 0.23% CGI81, 1.5% Norbloc, 11% PVP (MW 2,500), 0.02% Blue Hema, 0-2 ac PDMS, 29% t-amyl alcohol.

15 Lens C Contact lenses prepared as described in U.S. Pat. App. No. 60/318,536, entitled Biomedical Devices Containing Internal wetting Agents," filed on September 10, 2001 and its non-provisional counterpart of the same title, filed on September 6, 2002, containing by weight percent 28% Simma 2, 31% mPDMS, 23.5% DMA, 7% PVP (MW 360,000), 1.5%TEDGMA, 0.98% CGI 1850, 2.0% Norbloc, 6 HEMA, 0.02% Blue Hema.

Example 1

30 Preparation of Packages with Different Additives

Additives (identity and amounts listed in Table 1) were mixed with polypropylene (listed below). The material was injection molded to form the base portion of a contact lens package. The configuration of the package is as

illustrated in Figure 1 of U.S. Pat No. 5,467,868 which is hereby incorporated by reference.

Contact lenses made from aquafilcon A coated with polyhema, a silicone hydrogel, were added to individual polypropylene blister packs having 5 different additives containing 950 μ L of saline solution and then the blister pack was heat sealed with an flexible cover. Lenses were visually evaluated for adhesion to the package after sterilization. The flexible cover sheet was removed and the molded base is rotated or jiggled without spilling the saline solution while a contact lens is observed to determine if it is adhered to the 10 inner surface of the molded base. Lenses that do not adhere are free floating and pass the test. If the lenses adhere to the molded base in any manner they fail the test. The additive, its weight percentage, the number of lenses that stuck to the package, and number of lenses that were free floating are 15 displayed in Table 1. This example illustrates that glycerol monostearate is a superior additive.

TABLE 1

Polypropylene	Additive	# tested	# stuck
Exxon 1605	none	12	12
20 Exxon 1605	calcium stearate	36	36
Exxon 1605	2% glycerol monostearate	36	3
Exxon 1654	2% glycerol monostearate	84	2
Exxon 1654	none	12	12
Exxon Exxelor P1020	none	12	12
25 Fina EOD-0011	none	12	12
Fina EOD-0011	1% zinc stearate	12	12
Fina EOD-0011	3% zinc stearate	12	12
FINA 3924CW@	antistat	36	36

30 Example 2

Consumer Test

Packages containing 2% weight percent GMS and Exxon 1605 were prepared using the method of Example 1. Contact lenses of types A, B, and C

were added to individual blister packages along with 950 μL of saline solution. The filled packages were heat sealed with flexible covers and sterilized. The packaged lenses were submitted to consumers. The consumers opened the packages and evaluated the lenses for ease of removal of the lens from the

5 package using the following criteria and grading system

1-very easy removal-Lens comes out without any problems
2-easy removal-a couple of attempts to remove the lenses, but overall there were no real problems in removal
3-moderate removal- several tries before lens comes out, neither
10 pleased or displeased
4-difficult removal-many tries to remove with finger or nail-removal is frustrating
5-very difficult removal-many tries to remove with a finger or nail, lens damage upon removal- very unacceptable

15 Figure 1 illustrates the testing results for a comparison of Lens A in a polypropylene package (control), Lens A in a package containing 2.0% GMS where the package has an average surface roughness (Ra) of about 2.0 μm , and Len A in a package containing 2.0% GMS. This figure shows that the roughened package containing GMS has the highest consumer rating.

20 Figure 2 illustrates the testing results for a comparison of Lens B in a polypropylene package (control), Lens B in a package containing 2.0% GMS where the package has an average surface roughness (Ra) of about 2.0 μm , and Len B in a package containing 2.0% GMS. This figure shows that the
25 package containing 2.0 %GMS has the highest consumer rating.

Figure 3 illustrates the testing results for a comparison of Lens C in a polypropylene package (control), Lens C in a package containing 2.0% GMS where the package has an average surface roughness (Ra) of about 2.0 μm , and Len C in a package containing 2.0% GMS. This figure shows that the
30 package containing 2.0 %GMS has the highest consumer rating.

Example 3

Preparation of Packages With Different Additives

The testing methods and preparations of Example 1 were repeated with different additives and lens types as per Table 2. If "(UP)" appears in an entry, that bowl of the blister is shaped as in U.S. Pat. No. D 458,023. When the term "Rough Bowl" appears, the inside surface of the bowl is roughened to an Ra of 5 0.5mm to 0.8mm.

Table 2

	Base Resin	Lens Type	Tested	Stuck	Additive
10	Exxon 1605 PP	Lens B	15	13	Calcium stearate (2%)
	Exxon 1605 PP	Lens B	120	0	GMS (2%)
	Exxon 1605 PP	Lens C	30	0	GMS (2%)
	Exxon 1605 PP	Lens B	15	12	Dow Siloxane MB50-321 (10%)
	Exxon 1605 PP	Lens B	15	13	Dow Siloxane MB50-321 (5%)
	Exxon 1605 PP	Lens B	57	50	Ampacet 40604 99.5/.5 Erucamide
15	Ampacet 40604 PP	Lens B	15	15	Erucamide (5%)
	Exxon 1605 PP	Lens B	15	15	Kemamide (Erucamide) (5%)
	Exxon 1605 PP	Lens B	15	12	Superfloss anti-bock (2%)
	Exxon 1605 PP	Lens B	15	15	Zeospheres anti-block (2%)
	Exxon 1605 PP	Lens B	15	14	Superfloss anti-bock (2%) Oleamide (.2%)
20	Exxon 1605 PP	Lens B	14	13	Superfloss anti-bock (.2%) Oleamide (.2%)
	Exxon 1605 PP	Lens B	15	15	Talc (5%)
	Exxon 1605 PP	Lens B	15	13	Calcium carbonate (5%)
	Exxon 1605 PP	Lens B	15	14	Zinc stearate (5% hand blend)
	Exxon 1605 PP	Lens B	15	15	Zinc stearate (5% machine blend)
	Exxon 1605 PP	Lens B	15	14	ATP (Vitamin E) (5%)
	Exxon 1605 PP	Lens B	15	13	Licowax (1%)
25	Exxon 1605 PP	Lens B	15	14	Polyethyleneglycol monolaurate (5%)
	Exxon 1605 PP	Lens B	15	15	Mica (5%)
	Exxon 1605 PP	Lens B	175	8	Succinic Acid (5%)
	Exxon 1605 PP	Lens B	15	13	Succinic Anhydride (5%)
	Exxon 1605 PP	Lens B	118	22	Epolene E-43 (20% machine blend)
	Exxon 1605 PP	Lens B	100	92	Epolene E-43 (20% machine blend)
30	Exxon 1605 PP	Lens B	127	52	Epolene E-43 (10% hand blend)
	Exxon 1605 PP	Lens B	130	16	Epolene E-43 (10% machine blend)
	Exxon 1605 PP	Lens C	15	6	Epolene E-43 (10% machine blend)
	Exxon 1605 PP	Lens B	30	22	Epolene E-43 (5% machine blend)
	Exxon 1605 PP	Lens C	15	3	Epolene E-43 (5% machine blend)
	Exxon 1605 PP	Lens B	15	15	Atmer 163 (1%)
35	Exxon 1605 PP	Lens B	15	10	MC (5%)
	Exxon 1605 PP	Lens B	30	2	Boric Acid (5% hand blend)
	Exxon 1605 PP	Lens B	215	3	Boric Acid (5% machine blend)
	Exxon 1605 PP	Lens C	15	0	Boric Acid (5% machine blend)
	Exxon 1605 PP	Lens B	15	13	Boric Acid (3% hand blend)
40	Exxon 1605 PP	Lens B	15	15	Boric Acid (2% hand blend)
	Exxon 1605 PP	Lens B	150	4	Epolene E-43 (10% machine blend)
	Exxon 1605 PP	Lens B	50	9	Epolene E-43 (10% machine blend)
	Exxon 1605 PP	Lens B	50	15	Epolene E-43 (10% machine blend)
	Exxon 1605 PP	Lens B	50	35	Epolene E-43 (10% machine blend)
45	Exxon 1605 PP	Lens B	255	6	PVP K90 (5.0%)
	Exxon 1605 PP	Lens B	98	31	PVP K90 (2.5%)
	Exxon 1605 PP	Lens B	98	49	PVP K90 (1.25%)
	Exxon 1605 PP	Lens B	20	6	PVP K90 (1.0%)
	Exxon 1605 PP	Lens B	20	10	PVP K90 (.75%)
55	Exxon 1605 PP				

	Exxon 1605 PP	Lens B	20	17	PVP K90 (.5%)
	Exxon 1605 PP	Lens C	248	5	PVP K90 (5.0%)
	Exxon 1605 PP	Lens C	39	0	PVP K90 (10%) Blended down to 5%
5	Exxon 1605 PP	Lens C	135	42	PVP K90 (2.5%)
	Exxon 1605 PP	Lens C	135	54	PVP K90 (1.25%)
	Exxon 1605 PP	Lens C	70	42	PVP K90 (1.0%)
	Exxon 1605 PP	Lens C	70	50	PVP K90 (.75%)
	Exxon 1605 PP	Lens C	70	60	PVP K90 (.5%)
10	Exxon 1605 PP	Lens B	15	14	Nucrel 535 - 10.5% acid comonomer (2%)
	Exxon 1605 PP (3%)	Lens B	15	15	Nucrel 925 - 15% acid comonomer
15	Exxon 1605 PP (2%)	Lens C	15	14	Nucrel 535 - 10.5% acid comonomer
	Exxon 1605 PP (3%)	Lens C	15	14	Nucrel 925 - 15% acid comonomer
	Exxon 1605 PP	Lens B	15	15	2% XNAP with Pluronic
	Exxon 1605 PP	Lens C	15	14	2% XNAP with Pluronic
20	Exxon 1605 PP	Lens B	15	15	Pluronic 1%
	Exxon 1605 PP	Lens C	15	15	Pluronic 1%
	Exxon 1605 PP	Lens B	15	11	1% Tetronic
	Exxon 1605 PP	Lens C	15	15	1% Tetronic
	Exxon 1605 PP	Lens B	15	15	1% Flura
25	Exxon 1605 PP	Lens C	15	15	1% Flura
	Exxon 1605 PP	Lens B	30	23	2% Pluronic
	Exxon 1605 PP	Lens C	30	16	2% Pluronic
	Exxon 1605 PP	Lens C	77	0	PVP K90 (5%) + Epolene E43 (5%)
	Exxon 1605 PP	Lens B	50	0	PVP K90 (5%) + Epolene E43 (5%)
30	Exxon 1605 PP	Lens C	62	0	PVP K90 (5%) + Epolene E43 (1.5%)
	Exxon 1605 PP	Lens B	50	0	PVP K90 (5%) + Epolene E43 (1.5%)
35	Exxon 1605 PP	Lens C	65	0	PVP K90 (2.5%) + Epolene E43 (1.25%)
	Exxon 1605 PP	Lens B	50	0	PVP K90 (2.5%) + Epolene E43 (1.25%)
	Exxon 1605 PP	Lens C	115	10	PVP K90 (1%) + Epolene E43 (1%)
	Exxon 1605 PP	Lens B	100	11	PVP K90 (1%) + Epolene E43 (1%)
40	Exxon 1605 PP	Lens C	30	0	PVP K29/31 (5%)
	Exxon 1605 PP	Lens C	30	0	PVP K60 (5%)
	Exxon 1605 PP	Lens B	50	0	PVP K90 (1%) + Rough Bowl (UP)
	Exxon 1605 PP	Lens C	50	0	PVP K90 (1%) + Rough Bowl (UP)
	Exxon 1605 PP	Lens B	170	0	Epolene E43 (1%) + Rough Bowl
45	Exxon 1605 PP	Lens C	200	0	Epolene E43 (1%) + Rough Bowl

What is claimed is

1. A package for storing medical devices in a solution comprising a molded base wherein the molded base comprises an additive, provided that
5 the medical device is not a contact lens consisting of acqualfilcon A coated with polyHema.
2. The package of claim 1 wherein the additive is selected from the group consisting of succinic acid, glycerol monostearate, PVP, and PVP/maleic
10 anhydride.
3. The package of claim 1 wherein the additive is glycerol monostearate.
4. The package of claim 3 wherein glycerol monostearate is present at a
15 concentration of greater than about 0.5 weight percent to about 5 weight percent.
5. The package of claim 3 wherein glycerol monostearate is present at a
concentration of about 2 percent.
20
6. The package of claim 1 wherein the additive is PVP KD90.
7. The package of claim 6 wherein the PVP concentration is about 1% to
about 5%.
25
8. The package of claim 6 wherein the PVP concentration is about 1.0%.
9. The package of claim 1 wherein the additive is PVP KD90/maleic
anhydride.
30
10. The package of claim 9 wherein the PVP KD90/maleic anhydride
concentration is about 1/1% to about 5/5%.

11. The package of claim 1 wherein the medical device is a contact lens which comprises balafilcon A, lotrafilcon A, galyfilcon, senofilcon, or lenses disclosed in U.S. Pat. App. No. 60/318,536, entitled Biomedical Devices Containing Internal wetting Agents," filed on September 10, 2001 and its non-
5 provisional counterpart of the same title, filed on September 6, 2002.
12. The package of claim 11 wherein the contact lens comprises Simma 2 and mPDMS.

10 13. The package of claim 11 wherein the contact lens comprises Simma 2

14. The package of claim 1 wherein the molded base comprises polypropylene.

15 15. The package of claim 1 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 µm to about 20 µm.

16. The package of claim 15 wherein the inner surface has an average
20 roughness of about 1.8 µm to about 4.5 µm.

17. The package of claim 15 wherein the inner surface has an average roughness of about 1.9 µm to about 2.1 µm

25 18. The package of claim 15 wherein the inner surface has an average roughness of about 0.5 µm to about 0.8 µm.

19. The package of claim 1 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said
30 inner surface has an average roughness of about 0.5 µm to about 20 µm and the additive is glycerol monostearate or PVP.

20. The package of claim 19 wherein the average roughness of the inner surface is about 0.5 µm to about 0.8 µm and the concentration of PVP is about 1%.

5 21. The package of claim 19 wherein the inner surface has an average roughness of about 1.9 µm to about 2.1 µm and the concentration of PVP is about 1%.

10 22. The package of claim 1 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 µm to about 20 µm and the additive is maleic anhydride or PVP/maleic anhydride.

15 23. The package of claim 22 wherein the average roughness of the inner surface is about 0.5 µm to about 0.8 µm and the concentration of PVP/maleic anhydride is about 1%.

20 24. The package of claim 22 wherein the inner surface has an average roughness of about 1.9 µm to about 2.1 µm and the concentration of PVP/maleic anhydride is about 1%.

25 25. The package of claim 22 wherein the average roughness of the inner surface is about 0.5 µm to about 0.8 µm and the concentration of maleic anhydride is about 1%.

26. The package of claim 22 wherein the inner surface has an average roughness of about 1.9 µm to about 2.1 µm and the concentration of maleic anhydride is about 1%.

30 27. A method of reducing the adherence of a medical device to its packaging, comprising storing said medical device in a solution in a package comprising a molded base wherein said molded base comprises an additive,

provided that the medical device is not a contact lens consisting of acquafilcon A coated with polyHema.

28. The method of claim 27 wherein additive is selected from the group
5 consisting of succinic acid, glycerol monostearate, and PVP.

29. The method of claim 27 wherein the additive is glycerol monostearate.

30. The method of claim 27 wherein glycerol monostearate is present at a
10 concentration of greater than about 0.25 weight percent to about 5 weight
percent.

31. The method of claim 27 wherein glycerol monostearate is present at a
concentration of about 2 percent.

15

32. The method of claim 27 wherein the additive is PVP KD90.

33. The method of claim 27 wherein the PVP is present at about 1% to
about 5%.

20

34. The method of claim 27 wherein the contact lens comprises balafilcon A,
lotrafilcon A, or lenses disclosed in U.S. Pat. App. No. 60/318,536, entitled
Biomedical Devices Containing Internal wetting Agents," filed on September 10,
2001 and its non-provisional counterpart of the same title, filed on September
25 6, 2002.

35. The method of claim 27 wherein the contact lens comprises Simma 2

36. The method of claim 27 wherein the molded base comprises
30 polypropylene.

37. The method of claim 27 further comprising a cavity formed in said
molded base wherein said cavity comprises an inner surface, wherein said

inner surface has an average roughness of about 0.5 µm to about 20 µm and the additive is glycerol monostearate or PVP.

38. The method of claim 37 wherein the average roughness of the inner
5 surface is about 0.5 µm to about 0.8 µm and the concentration of PVP is about
1%.
10

39. The method of claim 37 wherein the inner surface has an average
roughness of about 1.9 µm to about 2.1 µm and the concentration of PVP is
10 about 1%.

40. The method of claim 27 further comprising a cavity formed in said
molded base wherein said cavity comprises an inner surface, wherein said
inner surface has an average roughness of about 0.5 µm to about 20 µm and
15 the additive is maleic anhydride or PVP/maleic anhydride.
20

41. The method of claim 40 wherein the average roughness of the inner
surface is about 0.5 µm to about 0.8 µm and the concentration of PVP/maleic
anhydride is about 1%.

42. The method of claim 40 wherein the inner surface has an average
roughness of about 1.9 µm to about 2.1 µm and the concentration of
PVP/maleic anhydride is about 1%.

25 43. The method of claim 40 wherein the average roughness of the inner
surface is about 0.5 µm to about 0.8 µm and the concentration of maleic
anhydride is about 1%.

44. The method of claim 40 wherein the inner surface has an average
30 roughness of about 1.9 µm to about 2.1 µm and the concentration of maleic
anhydride is about 1%.

45. A method of hydrating a contact lens comprising, consisting essentially of, or consisting of hydrating said lens in a molded base wherein said molded base comprises an additive.

5 46. The method of claim 45 wherein the additive is selected from the group consisting of succinic acid, glycerol monostearate, PVP, and PVP/maleic anhydride.


10 47. The method of claim 46 wherein the additives are present at a concentration of greater than about 0.25 weight percent to about 5 weight percent.

15 48. The method of claim 45 wherein the molded base further comprises a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 µm to about 20 µm and the additive is maleic anhydride or PVP/maleic anhydride.

1/3

FIG. 1


Lens A
Average Rating by Package Type



2/3

FIG. 2


Lens B
Average Rating by Package Type



3/3

FIG. 3

Lens C
Average Rating by Package Type



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060099 A3

(51) International Patent Classification⁷: A61L 12/08, A45C 11/00, 11/04, B65B 25/00

(74) Agents: JOHNSON, Philip S, et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(21) International Application Number:

PCT/US2003/039017

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 December 2003 (09.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/436,109 23 December 2002 (23.12.2002) US


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
2 September 2004

[Continued on next page]

(54) Title: MEDICAL DEVICE PACKAGES CONTAINING ADDITIVES



(57) Abstract: A package comprising a moulded base having an additive that presents the adhesion of a medical device enclosed in the package.

WO 2004/060099 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39017

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	A61L12/08	A45C11/00	A45C11/04	B65B25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L A45C B65B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/069896 A1 (PANKOW MARK L) 13 June 2002 (2002-06-13) paragraphs '0016!, '0072! -----	1,27
X	EP 0 367 513 A (BRITISH TECH GROUP) 9 May 1990 (1990-05-09) column 5, lines 17-21 column 6, lines 9-11 column 7, line 48 - column 8, line 11 -----	45
X	GB 2 078 760 A (METAL BOX CO LTD) 13 January 1982 (1982-01-13) page 1, lines 3-17 page 1, lines 43-45 -----	1-5, 14-19, 27-31, 36, 37 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 July 2004

Date of mailing of the international search report

23.07.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jochheim, J

INTERNATIONAL SEARCH REPORT

	Patent Application No PCT/US 03/39017
--	--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 033 326 A (JOHNSON & JOHNSON VISION CARE) 6 September 2000 (2000-09-06) paragraphs '0013!', '0018! - '0021!', '0041!; claims 1,16,17 -----	1,27
A	US 4 100 309 A (MICKLUS MICHAEL J ET AL) 11 July 1978 (1978-07-11) column 1, lines 8-48 -----	1,2,6, 15-18, 20,27, 28,33,37
A	DATABASE WPI Section Ch, Week 197737 Derwent Publications Ltd., London, GB; Class A96, AN 1977-65891Y XP002287714 & JP 52 093398 A (TOA IYO DENSHI KK) 5 August 1977 (1977-08-05) abstract -----	1,2,6-8, 14
A	US 4 981 657 A (RYDER FRANCIS E) 1 January 1991 (1991-01-01) column 2, lines 7-14; claim 1 -----	1,27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/39017

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 2 (part), 27, 28 (part)

A package for storing medical devices in a solution comprising a molded base wherein the molded base comprises a succinic acid additive.

A method of reducing the adherence of a medical device to its packaging, comprising storing said medical device in a solution in a package comprising a molded base and a succinic acid additive.

2. claims: 1, 2 (part), 27, 28 (part)

A package for storing medical devices in a solution comprising a molded base wherein the molded base comprises a glycerol monostearate additive.

A method of reducing the adherence of a medical device to its packaging, comprising storing said medical device in a solution in a package comprising a molded base and a glycerol monostearate additive.

3. claims: 1, 2 (part), 27, 28 (part)

A package for storing medical devices in a solution comprising a molded base wherein the molded base comprises a PVP additive.

A method of reducing the adherence of a medical device to its packaging, comprising storing said medical device in a solution in a package comprising a molded base and a PVP additive.

4. claims: 1, 2 (part), 27, 28 (part)

A package for storing medical devices in a solution comprising a molded base wherein the molded base comprises a PVP/maleic anhydride additive.

A method of reducing the adherence of a medical device to its packaging, comprising storing said medical device in a solution in a package comprising a molded base and a PVP/maleic anhydride additive.

5. claims: 45, 46 (part)

A method of hydrating a contact lens comprising, consistin essentially of, or consisting of hydrating said lens in a molded base wherein said molded base comprises a succinic acid additive.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. claims: 45, 46 (part)

A method of hydrating a contact lens comprising, consistin
essentially of, or consisting of hydrating said lens in a
molded base wherein said molded base comprises a glycerol
monostearate additive.

7. claims: 45, 46 (part)

A method of hydrating a contact lens comprising, consistin
essentially of, or consisting of hydrating said lens in a
molded base wherein said molded base comprises a PVP
additive.

8. claims: 45, 46 (part)

A method of hydrating a contact lens comprising, consistin
essentially of, or consisting of hydrating said lens in a
molded base wherein said molded base comprises a PVP/maleic
anhydride additive.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/39017

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2002069896	A1	13-06-2002	US	6280530 B1		28-08-2001
			AU	3115901 A		07-08-2001
			CA	2398245 A1		02-08-2001
			EP	1259333 A1		27-11-2002
			JP	2003521003 T		08-07-2003
			WO	0154834 A1		02-08-2001
EP 0367513	A	09-05-1990	AT	124649 T		15-07-1995
			AT	157301 T		15-09-1997
			AT	147323 T		15-01-1997
			AU	632071 B2		17-12-1992
			AU	4431489 A		10-05-1990
			CA	2001948 A1		02-05-1990
			CN	1043463 A ,B		04-07-1990
			CN	1065342 A ,B		14-10-1992
			CN	1122277 A ,B		15-05-1996
			DE	68923345 D1		10-08-1995
			DE	68923345 T2		21-12-1995
			DE	68927648 D1		20-02-1997
			DE	68927648 T2		24-04-1997
			DE	68928283 D1		02-10-1997
			DE	68928283 T2		02-01-1998
			DK	543789 A		03-05-1990
			DK	200000661 A		18-04-2000
			EP	0367513 A2		09-05-1990
			EP	0561480 A2		22-09-1993
			EP	0561481 A2		22-09-1993
			ES	2076216 T3		01-11-1995
			ES	2108208 T3		16-12-1997
			ES	2096846 T3		16-03-1997
			GB	2226272 A ,B		27-06-1990
			GB	2237240 A ,B		01-05-1991
			GB	2237241 A ,B		01-05-1991
			GR	3017372 T3		31-12-1995
			GR	3022419 T3		30-04-1997
			GR	3025140 T3		27-02-1998
			HK	16794 A		11-03-1994
			HK	16994 A		11-03-1994
			HK	74193 A		06-08-1993
			HK	133197 A		24-10-1997
			HK	1001228 A1		05-06-1998
			HK	1001251 A1		05-06-1998
			IN	175890 A1		21-10-1995
			IN	174309 A1		05-11-1994
			JP	1923651 C		25-04-1995
			JP	2172712 A		04-07-1990
			JP	6051305 B		06-07-1994
			SU	1838134 A3		30-08-1993
			RU	2044653 C1		27-09-1995
			US	5573108 A		12-11-1996
			US	5578332 A		26-11-1996
			US	5143660 A		01-09-1992
GB 2078760	A	13-01-1982	CA	1251746 A1		28-03-1989
			DE	3124196 A1		15-04-1982
			FR	2484955 A1		24-12-1981
			IN	153966 A1		08-09-1984
			IT	1137092 B		03-09-1986

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/39017

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
GB 2078760	A		ZA	8104025 A		30-06-1982
EP 1033326	A	06-09-2000	AU AU BR CA CN EP JP SG TW US	765985 B2 1954700 A 0001742 A 2299691 A1 1281687 A 1033326 A1 2000255642 A 85161 A1 514585 B 2002197478 A1		09-10-2003 07-09-2000 10-10-2000 01-09-2000 31-01-2001 06-09-2000 19-09-2000 19-12-2001 21-12-2002 26-12-2002
US 4100309	A	11-07-1978	AR AU AU BE BR CA CH CH DE FR GB IT JP JP JP MX NL SE SE US	219763 A1 512679 B2 3856878 A 869588 A1 7805057 A 1109344 A1 639675 A5 634590 A5 2828617 A1 2399879 A1 1600963 A 1109430 B 1246290 C 54029343 A 59019582 B 151865 A 7808290 A ,B, 441064 B 7808442 A 4119094 A		15-09-1980 23-10-1980 05-06-1980 01-12-1978 17-04-1979 22-09-1981 30-11-1983 15-02-1983 01-03-1979 09-03-1979 21-10-1981 16-12-1985 25-12-1984 05-03-1979 07-05-1984 11-04-1985 12-02-1979 09-09-1985 10-02-1979 10-10-1978
JP 52093398	A	05-08-1977	NONE			
US 4981657	A	01-01-1991	NONE			